Jefferies Raises Price Target on NeuroDerm (NDRM) to $42
Get Alerts NDRM Hot Sheet
Rating Summary:
4 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 14 | New: 22
Join SI Premium – FREE
Jefferies reiterated a Buy rating on Neuroderm Ltd (NASDAQ: NDRM), and raised the price target to $42.00 (from $40.00). After an FDA end-of-Phase II meeting, NeuroDerm plans to conduct comparative pharmacokinetic (PK) studies of ND0612L/H to pursue a bioavailability pathway, discontinuing Phase III efficacy studies.
Analyst Peter Welford commented, "We view a comparative bioavailability, rather than Phase III, US regulatory path for ND0612 to be lower risk and importantly suggests FDA is supportive of the product profile. This underscores our confidence for $1.7bn WW peak sales, now assuming 50% from 40% probability and unchanged 2019E launches. Our PT rises +5% to $42/share as the higher NPV is offset by dilution from the successful c.$75m follow-on."
For an analyst ratings summary and ratings history on Neuroderm Ltd click here. For more ratings news on Neuroderm Ltd click here.
Shares of Neuroderm Ltd closed at $19.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- China Resources Beer Holdings Co Ltd. (291:HK) (CRHKY) PT Raised to HK$44.67 at Jefferies
- WuXi AppTec Co Ltd (603259:CH) PT Lowered to RMB59.01 at Goldman Sachs
- Goldman Sachs Upgrades Win Semiconductors Corp (3105:TT) to Neutral
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!